

Bangladesh Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh			
2. Grant number(s): 1418-BGD-25b-X / 17-BGD-25e-X / 1718-BGD-25e-A / 14-BGD-08h-Y			
3. Date of Decision Letter: 21 December 2017			
4. Date of the Partnership Framework Agreement: 24 June 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Fractional use of Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID			
8. Programme duration²: 2015 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total ³
Routine Programme (US\$)	12,085,810 ⁴	2,612,000	14,697,810
Catch-up vaccination (US\$)	1,274,500	0	1,274,500
Total Budget (US\$)	13,360,310	2,612,000	15,972,310
Fragility, Emergencies and Refugees policy (Gavi supported)			
	2017	2018	Total ⁵
Catch-up vaccination (US\$)	122,000	37,000	159,000
Total Budget (US\$)	122,000	37,000	159,000
10. Vaccine introduction grant / Product switch grant: A VIG in the amount of US\$2,498,000 was disbursed on 14 August 2014. The use of residual funds from the IPV VIG to support the switch to fractional dose IPV was most recently approved on 20 September 2017.			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the total amount endorsed by Gavi for 2015 to 2018.

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)⁶

Number of vaccines to be purchased with Gavi funds	2015-2017	2018
fIPV Routine Programme (doses)		1,349,300
fIPV Catch-up vaccination (doses)		0
Annual Amounts (US\$)	13,360,310	2,612,000

Fragility, Emergencies and Refugees policy (Gavi supported)

Number of vaccines to be purchased with Gavi funds	2017	2018
fIPV Catch-up vaccination (doses)	62,900	18,900
Annual Amounts (US\$)	122,000	37,000

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Gavi's usual co-financing requirements do not apply to IPV.

15. Operational support for catch-up campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

⁶ This is the amount that Gavi has approved.

18. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

If Bangladesh envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Bangladesh.

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017